Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for

Transgene Announces Investor Meetings for January 2021: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene Announces Investor Meetings for January 2021


Regulatory News:



Transgene (Paris:TNG) (Euronext Paris: TNG) today announces that Management will participate in the upcoming investor events set out below.



Transgene will meet institutional

Agilent Announces Webcasts for Investment Community
Agilent Announces Webcasts for Investment Community


Agilent Technologies Inc. (NYSE: A) today announced dates and times of two upcoming webcasts for the investment community.



Goldman Sachs Healthcare CEOs Unscripted Conference
Tuesday, Jan. 5

Simulations Plus Publishes its Inaugural Environmental, Social and Governance (ESG) Report: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Publishes its Inaugural Environmental, Social and Governance (ESG) Report


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that

PerkinElmer to Present at J.P. Morgan Healthcare Conference: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24701/263px-PerkinElmer.svg.png
PerkinElmer to Present at J.P. Morgan Healthcare Conference


PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the annual J.P. Morgan Healthcare Conference on

Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia
Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia


Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the first set of

 
Quantum Genomics Signs a Strategic Contract with Delpharm
Quantum Genomics Signs a Strategic Contract with Delpharm

Delpharm Group selected for large-scale production of firibastat tablets to support clinical phase and future commercial needs

 

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a

Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia”) and Lonza Ltd. (SIX: LONN) ("Lonza") today announced they have expanded their exclusive manufacturing relationship. The parties

NANOBIOTIX Announces Closing of Global Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Global Offering to $113.3 Million: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg
NANOBIOTIX Announces Closing of Global Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Global Offering to $113.3 Million


Regulatory News:



NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer

Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the “Imaging and Robotics in Surgery (IRiS) Alliance”
Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the “Imaging and Robotics in Surgery (IRiS) Alliance”


Regulatory News:



Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’) a biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) and Mauna

Integra LifeSciences Selects Veeva Vault CDMS for Clinical Data Management
Integra LifeSciences Selects Veeva Vault CDMS for Clinical Data Management


Veeva Systems (NYSE: VEEV) today announced that Integra LifeSciences, a global leader in regenerative technologies, neurosurgical, and extremity orthopedic solutions, has selected Veeva Vault CDMS

 
Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran
Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran

Quantum Genomics to receive up to $12.1 million in upfront and milestone payments plus double-digit royalties on sales

Faran to receive an exclusive license to develop and commercialize firibastat

Sonova Invests €5 Million in Sensorion as the Companies Plan a Collaboration in Hearing Loss
Sonova Invests €5 Million in Sensorion as the Companies Plan a Collaboration in Hearing Loss


Regulatory News:



Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and

Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management


Veeva Systems (NYSE: VEEV) today announced that Samsung Biologics, an award-winning global contract development and manufacturing organization (CDMO), has adopted Veeva Vault QMS to streamline

Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management


Veeva Systems (NYSE: VEEV) today announced that Samsung Biologics, an award-winning global contract development and manufacturing organization (CDMO), has adopted Veeva Vault QMS to streamline

Agilent Receives Multiple Innovation Awards
Agilent Receives Multiple Innovation Awards


Agilent Technologies Inc. (NYSE: A) today announced that both the NanoDis System and the innovative new style polychromator in the 5800 and 5900 ICP-OES have received Innovation Awards from The

Novocure meldet nationale Kostenübernahme in der Schweiz für Optune® in Kombination mit Temozolomid zur Behandlung von neu diagnostiziertem Glioblastom: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure meldet nationale Kostenübernahme in der Schweiz für Optune® in Kombination mit Temozolomid zur Behandlung von neu diagnostiziertem Glioblastom


Novocure (NASDAQ:NVCR) gab heute bekannt, dass das Schweizerische Bundesamt für Gesundheit (BAG) Optune in Kombination mit Temozolomid mit Wirkung vom 1. April 2021 in die Mittel- und

Novocure Announces National Reimbursement in Switzerland for Optune® in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces National Reimbursement in Switzerland for Optune® in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma


Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of Remedies and Equipment (MiGeL) for the

U.S. CDC Committee of Independent Health Experts Recommends Vaccination with Pfizer and BioNTech COVID-19 Vaccine for Persons Ages 16 Years and Olderhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
U.S. CDC Committee of Independent Health Experts Recommends Vaccination with Pfizer and BioNTech COVID-19 Vaccine for Persons Ages 16 Years and Older


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted

Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19 http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration (FDA) has authorized the emergency use of the mRNA vaccine, BNT162b2, against

QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds and Price to Non-US Holders to Sell Outstanding Convertible Notes Due 2021
QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds and Price to Non-US Holders to Sell Outstanding Convertible Notes Due 2021


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces the successful pricing of the following series of transactions:



- The issue of new senior, unsecured

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 10, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement

Puma Biotechnology Presents Efficacy and Safety Outcomes from the Phase III NALA Trial at the 2020 SABCS: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Presents Efficacy and Safety Outcomes from the Phase III NALA Trial at the 2020 SABCS


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented efficacy and safety outcomes in a subgroup of patients from the NALA trial who had central nervous system (CNS)

Agilent Releases 2019 Corporate Social Responsibility Report
Agilent Releases 2019 Corporate Social Responsibility Report


Agilent Technologies Inc. (NYSE: A) today launched its 19th annual Corporate Social Responsibility (CSR) report, highlighting innovations and advancements achieved in 2019 and sharing the company’s

Pfizer Declares First-Quarter 2021 Dividendhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Declares First-Quarter 2021 Dividend


The board of directors of Pfizer Inc. (NYSE:PFE) declared a 39-cent first-quarter 2021 dividend on the company’s common stock, payable March 5, 2021, to holders of the Common Stock of record at the